Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Antibacterials & Antivirals

Emerging antibiotic resistance is a global challenge. Pfizer is committed to promoting the appropriate use of all antibiotics, so that they continue to fight infections when they are needed. Effective management of bacterial infections can be challenging, especially in patients with co-morbidities. Our antibacterial portfolio includes products which provide alternative therapeutic options for difficult-to-treat infections such as MRSA and multidrug-resistant infections that are resistant to traditional antibiotics.

Other drugs within our portfolio include

ACICLOVIR

(aciclovir sodium)

Summary of Product Characteristics

AMIKACIN

(amikacin sulfate)

Summary of Product Characteristics

CIPROFLOXACIN

(ciprofloxacin lactate)

Summary of Product Characteristics

DALACIN CREAM®

(clindamycin phosphate)

Summary of Product Characteristics

DALACIN® C

(clindamycin hydrochloride)

Summary of Product Characteristics

DALACIN® T

(clindamycin phosphate)

Summary of Product Characteristics

GENTAMICIN®

(gentamicin sulfate)

Summary of Product Characteristics

LEVOFLOXACIN

(levofloxacin hemihydrate)

Summary of Product Characteristics

MERONEM® IV

(meropenem trihydrate)

Summary of Product Characteristics

MYCOBUTIN®

(rifabutin)

Summary of Product Characteristics

TAZOCIN®

(piperacillin sodium + tazobactam sodium)

Summary of Product Characteristics

TOBRAMYCIN

(tobramycin)

Summary of Product Characteristics

VANCOMYCIN

(vancomycin)

Summary of Product Characteristics

VIBRAMYCIN™-D

(doxycycline monohydrate)

Summary of Product Characteristics

ZITHROMAX™

(azithromycin dihydrate)

Summary of Product Characteristics
Back to top